uBriGene Partners with XJTLU to Develop CAR-NK Cell Therapies for Solid Tumors
uBriGene, a China-based biotechnology company, has entered into a partnership with Xi’an Jiaotong-Liverpool University (XJTLU)...
Boehringer Ingelheim Partners with Sosei Group to Develop GPR52 Agonists for Schizophrenia
Boehringer Ingelheim (BI), headquartered in Germany, has entered into a global collaboration and exclusive option-to-license...
BeiGene’s Tislelizumab Receives FDA Approval for Esophageal Squamous Cell Carcinoma
BeiGene (NASDAQ: BGNE) has announced that the US Food and Drug Administration (FDA) has granted...
Hansoh Pharmaceutical Secures Global Rights to Biotheus’ BsAb HS-20117/PM1080
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a leading pharmaceutical company based in China, has...
Legend Biotech’s Carvykti Earns FDA Committee’s Unanimous Recommendation for Expanded Use
GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced...
Legend Biotech’s Carvykti Earns FDA Committee’s Unanimous Recommendation for Expanded Use
GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced...
Microenergy Medical Technology Secures Pre-Series A Funding to Advance Medical Devices
Microenergy Medical Technology Co., Ltd, a Hangzhou-based manufacturer of active intervention medical devices, has reportedly...
Getein Biotech Partners with Dymind Biotechnology to Advance IVD Market Presence
Getein Biotech Inc., (SHA: 603387), a company based in China with a focus on in...
CanSino Biologics Partners with Asymchem Laboratories to Innovate Biopharmaceutical Development
CanSino Biologics Inc., (HKG: 6185), a leading vaccine specialist based in China, has entered into...
Simcere Pharmaceutical’s Suvemcitug Files for Approval in China for Recurrent Ovarian Cancer
Simcere Pharmaceutical Group (HKG: 2096), a biopharmaceutical company based in China, has announced that an...
Bristol Myers Squibb’s Breyanzi Receives FDA Accelerated Approval for CLL/SLL Treatment
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s...
Sino Biopharmaceutical Advances Lanifibranor and TQA2225 into Late-Stage Clinical Trials for MASH
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the...
Mabwell’s Nectin-4 Targeting ADC 9MW2821 Shows Promise in Cervical Cancer Clinical Study
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...
Everest Medicines Stakeholders Pledge Six-Month Hold Amid Confidence in Long-Term Growth
Everest Medicines (HKG: 1952), a Chinese pharmaceutical firm, has received commitments from its controlling shareholder...
Novo Nordisk’s Wegovy Leads in Total US Prescriptions for Weight-Loss Market
Novo Nordisk (CPH: NOVO-B), a leading pharmaceutical company, has seen its weight-loss drug Wegovy (semaglutide)...
FDA Advisory Committee Backs Wider Use of Abecma in Relapsed or Refractory Multiple Myeloma
An advisory committee to the US Food and Drug Administration (FDA) has recommended the use...
Shanghai Henlius Initiates Phase I Trial for HLX42, an Innovative ADC Targeting EGFR
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first subject dosing in a Phase...
AstraZeneca Acquires Amolyt Pharma for $800 Million to Bolster Rare Disease Pipeline
AstraZeneca (AZ; NASDAQ: AZN) has finalized a definitive agreement to acquire France-based biopharmaceutical company Amolyt...
KeChow Pharma Secures Conditional Approval for HL-085, a First-of-Its-Kind MEK Inhibitor for Advanced Melanoma
Shanghai-based KeChow Pharma has received conditional marketing approval from the National Medical Products Administration (NMPA)...
Boehringer Ingelheim, J&J, and Novo Holdings Invest in Asgard Therapeutics for Cancer Immunotherapy
Germany’s Boehringer Ingelheim (BI), US-based Johnson & Johnson (J&J; NYSE: JNJ), and Denmark’s major Novo...